AAV8.hLCA5

Gene therapy

OOpus Genetics, Inc

AAV8.hLCA5 is one of 3 biologic programs targeting Retinal Degeneration. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal DegenerationActive, not recruiting

Retinal DegenerationPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Retinal Degeneration

#DrugCompanyPhaseTrials

Antabuse

Teva

Phase 2

2 2

Actimmune

HHorizon Therapeutics Ireland DAC

AAV8.hLCA5

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Retinal Degeneration

NCT05616793

Clinical

Trials by Indication[1]

Retinal Degeneration1 trial

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

Recruiting·OOpus Genetics, Inc·Phase 1/2·NCT05616793·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AAV8.hLCA5. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AAV8.hLCA5 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AAV8.hLCA5. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Opus Genetics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Company: OOpus Genetics, Inc

AAV8.hLCA5

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Retinal Degeneration1 trial

References

Drug Info

Quick Facts

Related News